Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment
- PMID:21704401
- DOI: 10.1016/j.radonc.2011.05.053
Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment
Abstract
Background and purpose: Tumor cells are recognized as being highly glycolytic. However, recently it was suggested that lactate produced in hypoxic tumor areas may be taken up by the monocarboxylate transporter MCT1 and oxidized in well-oxygenated tumor parts. Furthermore, it was shown that inhibition of lactate oxidation using the MCT1 inhibitor α-cyano-hydroxycinnamate (CHC) can radio-sensitize tumors possibly by forcing a switch from lactate oxidization to glycolysis in oxygenated cells, which in turn improves tumor oxygenation and indirectly kills radio-resistant hypoxic tumor cells from glucose starvation.
Material and methods: To provide direct evidence for the existence of a targetable energetic symbiosis, mice bearing SiHa or FaDu(dd) tumors were treated with CHC for different time periods. One hour prior to sacrifice, mice were administered with the glucose analog fluorodeoxyglucose (FDG) and the hypoxia-marker pimonidazole. Tumor cryosections were analyzed for regional glucose retention (FDG autoradiograms), hypoxia (pimonidazole retention) and glucose and lactate levels (bioluminescence imaging).
Results: Treatment did not influence metabolite concentrations, necrosis or extent of hypoxia, but pixel-by-pixel analysis comparing FDG retention and hypoxia (a measure of the apparent in vivo Pasteur effect) showed that CHC treatment caused a transient reduction in the Pasteur effect in FaDu(dd) 1.5 h following CHC administration whereas a reduction was only observed in SiHa following repeated treatments.
Conclusions: In summary, our data show that CHC is able to influence the intratumoral distribution of glucose use between hypoxic and non-hypoxic tumor areas. That is in accordance with a functional tumor lactate-shuttle, but the absence of any detectable changes in hypoxic extent and tissue metabolites was unexpected and warrants further investigation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.Sonveaux P, Végran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW.Sonveaux P, et al.J Clin Invest. 2008 Dec;118(12):3930-42. doi: 10.1172/JCI36843. Epub 2008 Nov 20.J Clin Invest. 2008.PMID:19033663Free PMC article.
- Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells.Feron O.Feron O.Radiother Oncol. 2009 Sep;92(3):329-33. doi: 10.1016/j.radonc.2009.06.025. Epub 2009 Jul 13.Radiother Oncol. 2009.PMID:19604589Review.
- Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice.Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W.Quennet V, et al.Radiother Oncol. 2006 Nov;81(2):130-5. doi: 10.1016/j.radonc.2006.08.012. Epub 2006 Sep 14.Radiother Oncol. 2006.PMID:16973228
- PET imaging of tumor hypoxia using 18F-labeled pimonidazole.Busk M, Jakobsen S, Horsman MR, Mortensen LS, Iversen AB, Overgaard J, Nordsmark M, Ji X, Lee DY, Raleigh JR.Busk M, et al.Acta Oncol. 2013 Oct;52(7):1300-7. doi: 10.3109/0284186X.2013.815797. Epub 2013 Aug 21.Acta Oncol. 2013.PMID:23962243
- Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?Vordermark D, Brown JM.Vordermark D, et al.Strahlenther Onkol. 2003 Dec;179(12):801-11. doi: 10.1007/s00066-003-1150-9.Strahlenther Onkol. 2003.PMID:14652668Review.
Cited by
- Dissecting the Proton Transport Pathway in Oral Squamous Cell Carcinoma: State of the Art and Theranostics Implications.Lorenzo-Pouso AI, Pérez-Sayáns M, Rodríguez-Zorrilla S, Chamorro-Petronacci C, García-García A.Lorenzo-Pouso AI, et al.Int J Mol Sci. 2019 Aug 29;20(17):4222. doi: 10.3390/ijms20174222.Int J Mol Sci. 2019.PMID:31470498Free PMC article.Review.
- Thyroid Cancer Metabolism: A Review.Gill KS, Tassone P, Hamilton J, Hjelm N, Luginbuhl A, Cognetti D, Tuluc M, Martinez-Outschoorn U, Johnson JM, Curry JM.Gill KS, et al.J Thyroid Disord Ther. 2016 Feb;5(1):200. doi: 10.4172/2167-7948.1000200. Epub 2016 Jan 14.J Thyroid Disord Ther. 2016.PMID:27213120Free PMC article.
- Targeting lactate metabolism for cancer therapeutics.Doherty JR, Cleveland JL.Doherty JR, et al.J Clin Invest. 2013 Sep;123(9):3685-92. doi: 10.1172/JCI69741. Epub 2013 Sep 3.J Clin Invest. 2013.PMID:23999443Free PMC article.Review.
- Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival.Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, Pettersen I, Al-Shibli K, Richardsen E, Busund LT, Bremnes RM.Eilertsen M, et al.PLoS One. 2014 Sep 16;9(9):e105038. doi: 10.1371/journal.pone.0105038. eCollection 2014.PLoS One. 2014.PMID:25225794Free PMC article.
- Dysfunctional T cell metabolism in the tumor microenvironment.Beckermann KE, Dudzinski SO, Rathmell JC.Beckermann KE, et al.Cytokine Growth Factor Rev. 2017 Jun;35:7-14. doi: 10.1016/j.cytogfr.2017.04.003. Epub 2017 Apr 23.Cytokine Growth Factor Rev. 2017.PMID:28456467Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources